ABVC BioPharma Secures $566,000 from ForSeeCon under Vitargus Licensing Agreement

ABVC BioPharma has received a cumulative total of $566,000 under its ForSeeCon licensing agreement for Vitargus production. This brings the total licensing revenue since the start of FY2025 to $1,345,950. The company plans to allocate the new licensing income to its GMP pharmaceutical facility in Hsinchu, Taiwan, to prepare for Vitargus production. ABVC's licensing framework with multiple partners positions it to capture near-term liquidity and long-term growth opportunities in CNS, oncology, and ophthalmology.